Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 4, 2007, Pages 387-393

  Munoz Calvo M T ^a   Barrios, V ^a   De Álvaro, M T García ^a   Lefort, M ^b   Mendez Davila C ^b   Argente, J ^a   De La Piedra, C ^b,c  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c Fundación Jiménez Díaz   (Spain)

Author keywords

Anorexia nervosa; Bone mineral density; Leptin; Osteoprotegerin; RANKL

Indexed keywords

ETHINYLESTRADIOL; GESTAGEN; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR;

ADOLESCENT; AMENORRHEA; ANOREXIA NERVOSA; ARTICLE; BONE DENSITY; CHILD NUTRITION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; LUMBAR VERTEBRA; MALNUTRITION; MENSTRUAL CYCLE; MOLECULAR EVOLUTION; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; AMENORRHEA; ANOREXIA NERVOSA; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; DENSITOMETRY, X-RAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPTIN; LUMBAR VERTEBRAE; MALNUTRITION; OSTEOPROTEGERIN; RADIOIMMUNOASSAY; RANK LIGAND; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 34250211442     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601110130     Document Type: Article

References (19)

1. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
2. Khosla S. Minireview. The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
3. Klein DA, Walsh BT. Eating disorders: clinical features and pathophysiology. Physiol Behav 2004;81:359-74.
4. Rodrigez-Cano T, Beato-Fernández L, Belmonte-Llario A. New contributions to the prevalence of eating disorders in Spanish adolescents: detection of false negatives. Eur Psychiat 2005;20:173-8.
5. Muñoz MT, Argente J. Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances. Eur J Endocrinol 2002;147:275-86.
6. Argente J, Barrios V, Chowen JA, Sinha MK, Considine RV. Leptin plasma levels in healthy Spanish children and adolescents, children with obesity, and adolescents with anorexia nervosa and bulimia nervosa. J Pediatr 1997;131:833-8.
7. Misra M, Soyka LA, Miller KK, Herzog DB, Grinspoon S, Dechen D, et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2003;88:3816-22.
8. Hernández M, Sánchez E, Sobradillo B. Curvas y tablas de crecimiento [Growing graphics and tables]. In: Argente J, Carrascosa A, Gracia R, Rodríguez F, editors. Tratado de endocrinología pediátrica y de la adolescencia [Pediatric endocrinology and adolescence book]. Barcelona: Doyma; 2000. pp 1333-51.
9. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 2004;4:295-300.
10. Kahl KG, Rudolf S, Dibbelt L, Stoeckelhuber BM, Gehl HB, Hohagen F, et al. Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. Osteoporos Int 2005;16:424-9.
11. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-27.
12. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
13. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-8.
14. Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 2003;88:5361-5.
15. Calero JA, Muñoz MT, Argente J, Traba ML, Méndez- Dávila C, García Moreno C, et al. A variation in bone alkaline phosphatase levels that correlates positively with bone loss and normal levels of aminoterminal propeptide of collagen I in girls with anorexia nervosa. Clin Chim Acta 1999;285:121-9.
16. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 2001;142:3546-53.
17. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140:1630-8.
18. Thomas T, Burguera B, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Riggs BL, et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001;29:114-20.
19. Tamasi JA, Arey BJ, Bertolini DR, Feyen JHM. Characterization of bone structure in leptin receptor-deficient Zucker (fa/fa) rats. J Bone Miner Res 2003;18:1605-11.